BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO
Conference Call Information
Date: Tuesday, April 29, 2014
Time: 9:00 a.m. eastern time
Toll-Free: (800) 708-4540
Toll: (847) 619-6397
Pass Code: 36946658
Webcast, including Replay and Conference Call Slides:
http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (Novartis). For more information on Array, please go to www.arraybiopharma.com
CONTACT: Tricia Haugeto Array BioPharma Inc. (303) 386-1193 thaugeto@arraybiopharma.com
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
SOURCE Array BioPharma Inc.